Suppr超能文献

使用酶免疫测定法测定原发性乳腺癌组织提取物中的c-erbB-2蛋白。

Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.

作者信息

Watanabe T, Fukutomi T, Tsuda H, Adachi I, Nanasawa T, Yamamoto H, Abe K

机构信息

Department of Medical Oncology, National Cancer Center Hospital, Tokyo.

出版信息

Jpn J Cancer Res. 1993 Dec;84(12):1279-86. doi: 10.1111/j.1349-7006.1993.tb02835.x.

Abstract

The c-erbB-2 protein in breast cancer tissue extract was determined by using an enzyme-immunoassay (EIA) to see whether the quantitative determination of the oncoprotein correlates with the results of immunohistochemistry and other prognostic factors. Primary breast cancer from 104 patients was assayed for c-erbB-2 protein with an EIA that used two monoclonal antibodies directed against the extracellular domain of the protein. Pelleted tissue homogenate prepared routinely for hormone receptor assay was used as the starting material. The mean quantity of c-erbB-2 protein was 695 unit/mg protein (range 23 to 5939), and this correlated well with the results of immunohistochemical staining (P < 0.00001). It was found that 17.3% (18/104) of all tumors contained amounts of c-erbB-2 protein exceeding 1000 units/mg protein. All tumors with negative or weakly positive staining contained the oncoprotein as less than 1000 units/mg protein. The content of c-erbB-2 protein was correlated with the histologic grade (P = 0.0022), mitotic index (P = 0.0002) and degree of nuclear atypia (P = 0.013). It was inversely correlated with progesterone receptor (P = 0.006) and less strongly with estrogen receptor status (P = 0.016). Values of hormone receptor concentration and c-erbB-2 protein content showed a hyperbolic relationship that suggested biological interactions between c-erbB-2 protein and steroid hormone receptors. We conclude that c-erbB-2 protein in tissue extracts of primary breast cancer can be determined reliably by EIA, and it seems feasible to explore further the advantages of introducing EIA as a routine laboratory examination for providing additional information about the biological aspects of breast cancer.

摘要

采用酶免疫分析法(EIA)测定乳腺癌组织提取物中的c-erbB-2蛋白,以观察该癌蛋白的定量测定是否与免疫组织化学结果及其他预后因素相关。使用针对该蛋白细胞外结构域的两种单克隆抗体,通过EIA对104例患者的原发性乳腺癌进行c-erbB-2蛋白检测。常规用于激素受体检测的沉淀组织匀浆用作起始材料。c-erbB-2蛋白的平均含量为695单位/毫克蛋白(范围为23至5939),这与免疫组织化学染色结果高度相关(P < 0.00001)。结果发现,所有肿瘤中有17.3%(18/104)的c-erbB-2蛋白含量超过1000单位/毫克蛋白。所有染色阴性或弱阳性的肿瘤中,癌蛋白含量均低于1000单位/毫克蛋白。c-erbB-2蛋白含量与组织学分级(P = 0.0022)、有丝分裂指数(P = 0.0002)和核异型程度(P = 0.013)相关。它与孕激素受体呈负相关(P = 0.006),与雌激素受体状态的相关性较弱(P = 0.016)。激素受体浓度值和c-erbB-2蛋白含量呈现双曲线关系,提示c-erbB-2蛋白与类固醇激素受体之间存在生物学相互作用。我们得出结论,原发性乳腺癌组织提取物中的c-erbB-2蛋白可通过EIA可靠测定,进一步探索将EIA作为常规实验室检查以提供有关乳腺癌生物学方面更多信息的优势似乎是可行的。

相似文献

2
Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.
Breast Cancer Res Treat. 1993 Dec;28(3):215-21. doi: 10.1007/BF00666582.

本文引用的文献

8
HER-2/neu oncogene protein and prognosis in breast cancer.HER-2/neu癌基因蛋白与乳腺癌预后
J Clin Oncol. 1989 Aug;7(8):1120-8. doi: 10.1200/JCO.1989.7.8.1120.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验